Predescu V, Riga D, Riga S, Turlea J, Bărbat I M, Botezat-Antonescu L
First Department of Psychiatry, Gh. Marinescu Clinical Hospital, Bucharest, Romania.
Ann N Y Acad Sci. 1994 Jun 30;717:315-31. doi: 10.1111/j.1749-6632.1994.tb12101.x.
A complex antiaging formula--Antagonic-Stress--was investigated vs. placebo (PL), meclofenoxate (MF)--neurometabolic nootropic and vs. nicergoline (NE)--cerebral vasodilator by comparative multiple trials (double-blind, randomized, and parallel) in gerontopsychiatry (DSM-III-R, 1987 and ICD-10, 1992 criteria). AS vs. PL studies in organic mental disorders--amnestic, depressive, anxiety, associated with axis III physical disorders or conditions, and in multiinfarct dementia were followed by AS vs. MF or NE investigations in senile dementia of Alzheimer's type. A total of 343 old people, distributed in 4 PL groups, 1 MF group, 1 NE group, and 5 AS groups were studied. Multiple investigations, before and after three-month treatments were made: psychometric evaluation by Sandoz Clinical Assessment-Geriatric, Self-Assessment Scale-Geriatric and their 5 subscales; psychopathological rating by Hamilton Depression and Anxiety Scales; as well as psychometric testing by digit symbol of WAIS, Wechsler Memory Scale and Wechsler Adult Intelligence Scale (WAIS). Except PL, prolonged and large dose treatments with these cerebral activators (MF, NE and especially AS) reduced the psychogeriatric-psychopathological scores and the deterioration index, and improved cognitive performance. The therapeutical effectiveness of AS multiple formula in gerontopsychiatry and its superiority vs. monotherapy (MF or NE) are discussed in connection with its complex neurometabolic and synergetic composition, multiple antioxidative combinations, free radical scavengers, lipofuscinolytic agents, the antiischemic action of antioxidants, multivitamin and multimineral supplementation, and with the better efficacy of multitherapy vs. monotherapy in geriatrics.
通过老年精神病学领域的多项比较试验（双盲、随机和平行试验，依据1987年《精神疾病诊断与统计手册》第三版修订本（DSM - III - R）及1992年《国际疾病分类》第十版（ICD - 10）标准），对一种复杂的抗衰老配方——抗应激配方（Antagonic - Stress，简称AS）与安慰剂（PL）、氯酯醒（MF，一种神经代谢益智药）以及尼麦角林（NE，一种脑血管扩张剂）进行了研究。在针对器质性精神障碍（包括遗忘型、抑郁型、焦虑型，与躯体疾病或状况相关的轴III型障碍）以及多发梗死性痴呆进行的AS与PL对比研究之后，又开展了AS与MF或NE在阿尔茨海默型老年痴呆中的对比研究。共对343名老年人进行了研究，他们被分为4个PL组、1个MF组、1个NE组和5个AS组。在为期三个月的治疗前后进行了多项调查：采用山德士临床评估 - 老年版、老年自我评估量表及其5个分量表进行心理测量评估；通过汉密尔顿抑郁和焦虑量表进行精神病理学评分；以及采用韦氏成人智力量表（WAIS）的数字符号测验、韦氏记忆量表和韦氏成人智力量表进行心理测量测试。除PL外，使用这些脑激活剂（MF、NE，尤其是AS）进行长期大剂量治疗可降低老年精神病理学评分和恶化指数，并改善认知表现。结合其复杂的神经代谢和协同成分、多种抗氧化组合、自由基清除剂、脂褐素溶解剂、抗氧化剂的抗缺血作用、多种维生素和矿物质补充，以及多药联合治疗在老年病学中优于单一疗法的效果，讨论了AS复合配方在老年精神病学中的治疗效果及其相对于单一疗法（MF或NE）的优越性。
